Pipeline Clinical Studies

Summary – our clinical studies

Our clinical development program will provide us with a broad set of data and information about melflufen’s efficacy in various patient groups. We initiated preparations for an NDA submission based on t...

BRIDGE

SUPPORTING Ongoing phase 2 study with up to 25 patients Open-label, single-arm study for patients with reduced renal function Positioning study to show melflufen’s treatment profile within this patient g...

ANCHOR

EXPLORATIVE Ongoing phase 1/2 study with up to 64 patients The patients have received 1–4 earlier lines of therapy including IMiDs and PIs Demonstrates how melflufen can be administered as a combination t...

OCEAN

CONFIRMATORY Ongoing phase 3 study which will include more than 450 patients, including RRMM patients who are refractory to lenalidomide Direct comparison with pomalidomide in patients treated with IMiDs...

HORIZON

PIVOTAL STUDY Ongoing phase 2 study in 157 patients RRMM patients with few or no remaining treatment options Patients have received >2 earlier lines of therapy with IMiDs and PIs and are refractory...

O-12-M1

SUPPORTING Completed phase 2 clinical study with 45 patients Included RRMM patients who had received a median of 4 prior lines of therapy, and became refractory to lenalidomide (immunomodulatory pharmaceutical...